April 4th, 2020

A full text version of this article is available.
To access article obtain online access here or login
Antenatal Corticosteroids Increase the Risk of Hyperglycemia in Nonobese and Obese Nondiabetic Women
Authors:  Tara A. Lynch, M.D., Johanna C. Bringley, D.O., Erin C. Crosby, M.D., Kevin C. Kiley, M.D., and Asha Rijhsinghani, M.D.
  OBJECTIVE: The administration of antenatal cortico­ steroids is widely used in obstetrics for women at risk for preterm delivery. A commonly recognized side effect is maternal hyperglycemia. The impact of obesity on the level of hyperglycemia after corticosteroid administration in nondiabetic women is unknown.

STUDY DESIGN: A retro­spective study evaluating the relationship between obesity class and rates of hyperglycemia in nondiabetic women after the administration of antenatal corticosteroids. All nondiabetic women ad­ mitted to a single academic institution from January 2013–July 2015 who were monitored for hyperglycemia with blood glucose levels following corticosteroid admin­istration were included. The main outcome measure was rate of hyperglycemia stratified based on body mass index.

RESULTS: All women had elevated glucose levels after the administration of antenatal corticosteroids. Specifi­cally, 74.5% of patients had an initial glucose level ≥110 mg/dL and 94.1% had a maximum glucose ≥110 mg/dL. Nonobese patients had higher mean maximum glucose than did obese women.

CONCLUSION: As both nonobese and obese women have high rates of post­corticosteroid hyperglycemia, there may be a role for the monitoring of blood glucose levels in nondiabetic women, regardless of body mass index.
Keywords:  antenatal corticosteroids, betamethasone, diabetes mellitus, gestational diabetes, hyperglycemia, neonatal hypoglycemia, obesity, pregnancy, preterm birth, risk
  Acrobat Reader 7.0 is recommended to properly view and print the article.
Reader can be downloaded from